0000000000014537

AUTHOR

Alice Engel

showing 12 related works from this author

Early improvement as a resilience signal predicting later remission to antidepressant treatment in patients with Major Depressive Disorder: Systemati…

2017

Early improvement of depressive symptoms during the first two weeks of antidepressant treatment has been discussed to be a resilience signal predicting a later positive treatment outcome in patients with Major Depressive Disorder (MDD). However, the predictive value of early improvement varies between studies, and the use of different antidepressants may explain heterogeneous results. The objective of this review was to assess the predictive value of early improvement on later response and remission and to identify antidepressants with the highest chance of early improvement. We included 17 randomized controlled trials investigating early improvement in 14,779 adult patients with MDD compar…

medicine.medical_specialtymedicine.drug_classmedia_common.quotation_subjectMirtazapineTricyclic antidepressantPlacebolaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicineOutcome Assessment Health CaremedicineHumansPsychiatryBiological Psychiatrymedia_commonDepressive Disorder MajorResilience Psychologicalmedicine.diseaseAntidepressive Agents030227 psychiatryPsychiatry and Mental healthMeta-analysisAntidepressantMajor depressive disorderPsychological resiliencePsychology030217 neurology & neurosurgerymedicine.drugJournal of psychiatric research
researchProduct

Blood laboratory findings in patients suffering from self-perceived electromagnetic hypersensitivity (EHS)

2009

Risks from electromagnetic devices are of considerable concern. Electrohypersensitive (EHS) persons attribute a variety of rather unspecific symptoms to exposure to electromagnetic fields. The pathophysiology of EHS is unknown and therapy remains a challenge. We hypothesized that some electrosensitive individuals are suffering from common somatic health problems. Toward this end we analysed clinical laboratory parameters including thyroid-stimulating hormone (TSH), alanine transaminase (ALT), aspartate transaminase (AST), creatinine, hemoglobine, hematocrit and c-reactive protein (CRP) in subjects suffering from EHS and in controls that are routinely used in clinical medicine to identify or…

AdultMalemedicine.medical_specialtyPhysiologyBiophysicsThyrotropinAspartate transaminaseHematocritElectromagnetic hypersensitivitychemistry.chemical_compoundElectromagnetic FieldsInternal medicineHypersensitivitymedicineHumansRadiology Nuclear Medicine and imagingIn patientAspartate AminotransferasesAgedInflammationCreatininebiologymedicine.diagnostic_testbusiness.industryLiver DiseasesAlanine TransaminaseAnemiaGeneral MedicineMiddle AgedThyroid DiseasesPathophysiologyC-Reactive ProteinEndocrinologychemistryAlanine transaminaseCreatininebiology.proteinFemalePerceptionmedicine.symptombusinessHormoneBioelectromagnetics
researchProduct

Randomized controlled study of early medication change for non-improvers to antidepressant therapy in major depression – The EMC trial

2015

Patients with Major Depressive Disorder (MDD) and no improvement after two weeks of antidepressant pharmacotherapy have a high risk of treatment failure. The aim of the study was to determine whether an early medication change (EMC) strategy is superior to a guideline-based treatment in MDD patients without improvement after two weeks of antidepressant pharmacotherapy. Eight-hundred-and-eighty-nine patients with MDD were enrolled, 879 patients received the SSRI escitalopram. Of those, 192 patients had no improvement, defined as a reduction of < 20% on the Hamilton Depression Rating Scale (HAMD-17) after 14 days of treatment, and were randomly assigned to open treatment with the EMC strategy…

AdultMalemedicine.medical_specialtyAdolescentCitalopramLithiumCitalopramlaw.inventionDepressive Disorder Treatment-ResistantYoung Adult03 medical and health sciences0302 clinical medicinePharmacotherapyRandomized controlled triallawEarly Medical InterventionInternal medicinemedicineHumansEscitalopramPharmacology (medical)PsychiatryBiological PsychiatryAgedPharmacologyVenlafaxine HydrochlorideGuidelineMiddle Agedmedicine.diseaseAntidepressive Agents030227 psychiatryClinical trialPsychiatry and Mental healthTreatment OutcomeNeurologyDelayed-Action PreparationsAntidepressive Agents Second-GenerationAntidepressantMajor depressive disorderDrug Therapy CombinationFemaleNeurology (clinical)Psychology030217 neurology & neurosurgerymedicine.drugEuropean Neuropsychopharmacology
researchProduct

Peripheral Leptin Levels in Narcoleptic Patients

2007

Narcolepsy is a severe sleep disorder that in most patients is characterized by the deficiency of central orexin. Clinically, narcolepsy is associated with obesity. Currently, there is a literature controversy about the potential alteration of leptin levels in narcoleptic patients. Theoretically, diminished leptin levels could partially contribute to the observed overweight of patients. Two studies have reported decreased leptin levels, whereas a larger, recent study failed to detect differences between patients and controls.To help settle the controversy, we have measured peripheral leptin levels in 42 narcoleptic patients and in 31 body mass index-matched controls.No significant differenc…

AdultLeptinMalemedicine.medical_specialtyEndocrinology Diabetes and Metabolismmacromolecular substancesBody Mass IndexEndocrinologyReference ValuesDiabetes mellitusInternal medicineHumansMedicineAgedNarcolepsySleep disorderbusiness.industryLeptinMiddle Agedmedicine.diseaseObesityPeripheralOrexinMedical Laboratory TechnologyEndocrinologynervous systemFemalebusinessNarcolepsyDiabetes Technology &amp; Therapeutics
researchProduct

Heavy metal exposure in patients suffering from electromagnetic hypersensitivity

2009

Abstract Background Risks from electromagnetic devices are of considerable concern. Electrohypersensitive (EHS) persons attribute a variety of rather unspecific symptoms to the exposure to electromagnetic fields. The pathophysiology of EHS is unknown and therapy remains a challenge. Objectives Heavy metal load has been discussed as a potential factor in the symptomatology of EHS patients. The main objective of the study was to test the hypothesis of a link between EHS and heavy metal exposure. Methods We measured lead, mercury and cadmium concentrations in the blood of 132 patients ( n  = 42 males and n  = 90 females) and 101 controls ( n  = 34 males and n  = 67 females). Results Our result…

Malemedicine.medical_specialtyEnvironmental EngineeringElectromagnetic hypersensitivityElectromagnetic FieldsMetals HeavyInternal medicineHypersensitivitymedicineElectromagnetic devicesHumansEnvironmental ChemistryIn patientWaste Management and DisposalMercury bloodHeavy metal detoxificationChemistryHeavy metalsEnvironmental ExposureMercuryMiddle AgedPollutionLeadEnvironmental chemistryBody BurdenFemaleLead bloodmedicine.symptomCadmiumScience of The Total Environment
researchProduct

Elevated peripheral visfatin levels in narcoleptic patients.

2008

OBJECTIVE: Narcolepsy is a severe sleep disorder that is characterized by excessive daytime sleepiness, cataplexies and a tendency towards obesity. Recent discoveries indicate that the major pathophysiology is a loss of hypocretin (orexin) producing neurons due to immunologically mediated degeneration. Visfatin is a recently described proinflammatory adipokine. It is identical to the immune modulating pre-B-cell colony enhancing factor (PBEF). Our study examines the hypothesis that visfatin levels are altered in narcoleptic patients. METHODS: For the analysis, a total of n = 54 patients (n = 18 males and n = 36 females) with the diagnosis of narcolepsy according to DSM-IV and the Internatio…

AdultMalemedicine.medical_specialtyPolysomnographyNicotinamide phosphoribosyltransferaseAdipokineExcessive daytime sleepinesslcsh:MedicinePolysomnographyBody Mass IndexProinflammatory cytokineDiabetes and Endocrinology/Obesitychemistry.chemical_compoundReference ValuesInternal medicinemedicineHumansHLA-DR2 AntigenAge of OnsetNicotinamide Phosphoribosyltransferaselcsh:ScienceAgedNarcolepsySleep disorderMultidisciplinarymedicine.diagnostic_testbusiness.industrylcsh:RMiddle Agedmedicine.diseaseOrexinEndocrinologyMental Health/Sleep Disordersnervous systemchemistryImmunologyCytokinesFemalelcsh:Qmedicine.symptomImmunology/Genetics of the Immune SystembusinessResearch ArticleNarcolepsyPLoS ONE
researchProduct

A combined marker of early non-improvement and the occurrence of melancholic features improve the treatment prediction in patients with Major Depress…

2017

Abstract Background Early Improvement of depressive symptoms within two weeks of antidepressant treatment is a highly sensitive but less specific predictor of later treatment outcome. The aim of this study was to identify clinical features at treatment initiation which are associated with early improvement and non-improvement as well as to identify variables predicting non-remission in patients showing an early improvement. Methods 889 patients with a major depressive episode according to DSM-IV who had participated in an antidepressant treatment trial served as study sample. Clinical predictors (demographic variables, psychopathology, comorbid disorders) were analysed in 698 (79%) early im…

AdultMalemedicine.medical_specialtyComorbidityAvoidant personality disorderPatient ReadmissionSeverity of Illness IndexSuicidal Ideation03 medical and health sciences0302 clinical medicineRisk FactorsRating scaleInternal medicinemedicineHumansMajor depressive episodePsychiatryAtypical depressionDepression (differential diagnoses)Depressive Disorder Majorbusiness.industryMiddle Agedmedicine.diseaseAntidepressive Agents030227 psychiatryPsychiatry and Mental healthClinical PsychologyTreatment OutcomeMajor depressive disorderAntidepressantFemalemedicine.symptombusiness030217 neurology & neurosurgeryPsychopathologyJournal of Affective Disorders
researchProduct

Post H1N1 vaccination narcolepsy–cataplexy with decreased CSF beta-amyloid

2012

VaccinationNarcolepsy with cataplexyAmyloidbusiness.industryImmunologyMedicineGeneral MedicinebusinessBeta (finance)Sleep Medicine
researchProduct

Basal metabolic rate in narcoleptic patients.

2009

PATIENTS SUFFERING FROM NARCOLEPSY TEND TO BE OBESE.1,2 AMONG OTHER HYPOTHESES LOWER RESTING ENERGY EXPENDITURE HAS BEEN SUSPECTED to be the cause of the narcolepsy-associated obesity.3,4 The use of indirect calorimetry is a well-established noninvasive method to measure the energy expenditure (EE) and the resting (basal) metabolic rate (BMR). Chabas et al. recently published an evaluation of eating behavior and energy balance of 7 typical and 6 atypical narcoleptic patients and 9 controls using indirect calorimetry. Narcoleptic patients were found to have a lower energy expenditure (EE) than controls (n = 13, P = 0.07). Thus, it was concluded that narcolepsy associated obesity could be the…

AdultMalemedicine.medical_specialtyShort NoteLower energyBody Mass IndexBasal (phylogenetics)Physiology (medical)Internal medicineGermanymedicineHumansResting energy expenditureObesityNarcolepsyCalorimetry Indirectmedicine.diseaseObesityEndocrinologyBasal metabolic rateMetabolic rateFemaleNeurology (clinical)Basal MetabolismPsychologyEnergy MetabolismBody mass indexNarcolepsySleep
researchProduct

Investigation of insulin resistance in narcoleptic patients: dependent or independent of body mass index?

2011

Alice Engel1,2, Jana Helfrich1, Nina Manderscheid1, Petra B Musholt3, Thomas Forst3, Andreas Pf&amp;uuml;tzner3, Norbert Dahmen1,21Department of Psychiatry, University of Mainz, Germany; 2Fachklinik Katzenelnbogen, Katzenelnbogen, Germany; 3IKFE, Institute for Clinical Research and Development, Mainz, GermanyBackground: Narcolepsy is a severe sleep-wake cycle disorder resulting in most cases from a lack of orexin, the energy balance-regulating hormone. Narcoleptic patients have been reported to suffer from an excess morbidity of Type 2 diabetes, even after correction for their often elevated body mass index.Methods: To explore whether narcolepsy is specifically associated with a propensity …

insulinobesitymedicine.medical_specialtyPathologyNeuropsychiatric Disease and Treatmentmedicine.medical_treatmentnarcolepsyNeurosciences. Biological psychiatry. NeuropsychiatryType 2 diabetesInsulin resistanceInternal medicinemedicineintact proinsulinRC346-429Biological PsychiatryOriginal ResearchProinsulinbusiness.industryInsulinmedicine.diseaseOrexinPsychiatry and Mental healthEndocrinologyHomeostatic model assessmentNeurology. Diseases of the nervous systemfasting glucosebusinessBody mass indexRC321-571NarcolepsyNeuropsychiatric Disease and Treatment
researchProduct

Appetite and Obesity

2011

Orexin (hypocretin) plays an important role in promoting wakefulness [1]. It stimulates wakefulness when injected in the cerebral ventricles, in the periventricular nucleus, dorsomedial hypothalamus, or lateral hypothalamus [2, 3]. Orexinergic neurons originate from the lateral hypothalamus and have projections to most parts of the central nervous system including the brain stem. The lack of orexin and/or orexin receptors is linked to narcolepsy [4–6].

medicine.medical_specialtyLateral hypothalamusbusiness.industrymedia_common.quotation_subjectdigestive oral and skin physiologyAppetitemedicine.diseaseOrexin receptorOrexinEndocrinologymedicine.anatomical_structurenervous systemHypothalamusInternal medicinemental disordersmedicineWakefulnessPeriventricular nucleusbusinesshormones hormone substitutes and hormone antagonistspsychological phenomena and processesNarcolepsymedia_common
researchProduct

Prevalence of eating disorders and eating attacks in narcolepsy

2008

Norbert Dahmen, Julia Becht, Alice Engel, Monika Thommes, Peter TonnPsychiatry Department, University of Mainz, GermanyAbstract: Narcoleptic patients suffer frequently from obesity and type II diabetes. Most patients show a deficit in the energy balance regulating orexinergic system. Nevertheless, it is not known, why narcoleptic patients tend to be obese. We examined 116 narcoleptic patients and 80 controls with the structured interview for anorectic and bulimic eating disorders (SIAB) to test the hypothesis that typical or atypical eating attacks or eating disorders may be more frequent in narcoleptic patients. No difference in the current prevalence of eating disorders bulimia nervosa, b…

medicine.medical_specialtyNeuropsychiatric Disease and TreatmentnarcolepsyNeurosciences. Biological psychiatry. NeuropsychiatryAnorexiaAnorexia nervosaeating attackBinge-eating disordermental disordersMedicinePsychiatryRC346-429Biological PsychiatryOriginal Researchbusiness.industryBulimia nervosadigestive oral and skin physiologymedicine.diseaseObesityPsychiatry and Mental healthEating disordersbulimiaanorexiaeating disorderAnorecticSIABNeurology. Diseases of the nervous systemmedicine.symptombusinessNarcolepsyRC321-571Neuropsychiatric Disease and Treatment
researchProduct